Reference	Treatment Arms	Sample Size, n	Age, yrs	Male, %	Comorbidities, %				Follow-up, Months	Primary Endpoint
					Hypertension	MI	Diabetes	Smokers
Chen et al., 2011	Provisional	185	64.6 ± 9.9	78.9	60.5	14.1	23.8	23.8	6, 12	MACE
	Complex	185	63.9 ± 11.1	76.2	65.4	17.3	19.5	30.8
Chen et al., 2014	Provisional	2,552	65.0 ± 10.0	74.9	72.5	9.3	34.3	12.5	12	MACE
	Complex	1,108	68.0 ± 9.0	78	74	12.2	45	6.8
Chen et al., 2017	Provisional	183	64.7 ± 10.0	75.8	60.9	14.2	23.1	NR	60	MACE
	Complex	183	63.9 ± 11.1	78.8	65.2	17.4	19.6	NR
Colombo et al., 2009	Provisional	173	67.0 ± 10.0	76.3	79.8	35.3	22	16.8	6	MACE
	Complex	177	65.0 ± 10.0	80.2	70.6	44.6	23.7	20.3
Ferenc et al., 2008	Provisional	101	66.7 ± 9.2	79.4	92.1	18.8	25.7	9.9	9	MACE
	Complex	101	66.9 ± 10.5	78.2	89.1	20.8	18.8	13.9
Généreux et al., 2015	Provisional	349	64.6 ± 9.4	73.4	73.6	37.8	30	15.2	9	TVF
	Tryton	355	64.5 ± 10.6	71.8	73.2	28.1	23.9	17.5
Généreux et al., 2016	Provisional	143	65.2 ± 9.2	81.8	76.8	40.4	28.7	15.5	9	TVF
	Tryton	146	64.5 ± 10.7	79.5	68.5	29.7	25.3	17.1
Hildick-Smith et al., 2010	Provisional	250	64.0 ± 10.0	77	57	23	13	17	9	Composite Index*
	Complex	250	64.0 ± 11.0	77	62	25	11	17
Hildick-Smith et al., 2016	Provisional	103	62.9 ± 10.8	85	63	39	25	56	12	Composite Index*
	Complex	97	63.5 ± 12.1	78	68	41	31	50